Stay updated on PDR001/MBG453 w/ Decitabine in AML Clinical Trial

Sign up to get notified when there's something new on the PDR001/MBG453 w/ Decitabine in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PDR001/MBG453 w/ Decitabine in AML Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The record describes Novartis’s completed Phase 1b study of PDR001 and/or MBG453 with decitabine or azacitidine for AML and high-risk MDS, including its study arms, eligibility criteria, locations, and outcome measures. It also indicates that no results are posted.
    Difference
    74%
    Check dated 2026-11-08T05:21:52.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0. The study record page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T02:20:04.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A site-wide banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T02:21:31.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-18T02:09:45.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T03:09:55.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The study page was updated to revision v3.7.0, and several sections such as plain-language trial summary, results, sponsor references, and related regulatory/ keywords were removed from the listing. This changes how the study is presented and navigated.
    Difference
    21%
    Check dated 2026-09-20T01:16:40.000Z thumbnail image

Stay in the know with updates to PDR001/MBG453 w/ Decitabine in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PDR001/MBG453 w/ Decitabine in AML Clinical Trial page.